Clinical Trial Update: Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacokinetic study of a recombinant Factor IX albumin fusion protein in people with Hemophilia B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Factor IX-albumin fusion protein (recombinant coagulation factor IX albumin fusion protein)

Snippet

Sponsor: CSL Behring | Conditions: Hemophilia B | Phase 1 | Status: COMPLETED